Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Chemotherapy in EGFR-mutated Lung Cancer
NCT00949650Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of afatinib in lung adenocarcinoma, sponsored by Boehringer Ingelheim. Started Aug 2009; status: completed.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00949650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00949650.